Exclusive Summary

• - Core Lialda (1.2 g DR, MMX) patents have expired in the US/EU; generics have been on the market since 2019–2020, enabling rapid multi-country entry.
• - UC affects ~4–6 million people globally; ~70–80% are mild–moderate and >60% use oral 5-ASA at some point, supporting steady long-term demand.
• - Once-daily 1.2 g tablets reduce pill burden for 2.4–4.8 g/day regimens and are first-line for mild–moderate UC per ACG/AGA/ECCO/BSG (also listed on the WHO EML).
• - US-FDA GMP and US registration validate quality/BE equivalence, with a CTD package that accelerates registrations and tenders in MENA/LatAm/SEA.
• - Versus brand, mature generic markets typically realize 50–90% cost savings; in markets lacking 1.2 g strength, this offers clear differentiation and volume upside.